CA2898565C - Treatment of graft versus host disease in transplant patients - Google Patents

Treatment of graft versus host disease in transplant patients Download PDF

Info

Publication number
CA2898565C
CA2898565C CA2898565A CA2898565A CA2898565C CA 2898565 C CA2898565 C CA 2898565C CA 2898565 A CA2898565 A CA 2898565A CA 2898565 A CA2898565 A CA 2898565A CA 2898565 C CA2898565 C CA 2898565C
Authority
CA
Canada
Prior art keywords
compound
conditioning
hsct
days
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2898565A
Other languages
English (en)
French (fr)
Other versions
CA2898565A1 (en
Inventor
Peter Gergely
Kazuhiko Kuriyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Priothera Ltd
Original Assignee
Priothera Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Priothera Ltd filed Critical Priothera Ltd
Publication of CA2898565A1 publication Critical patent/CA2898565A1/en
Application granted granted Critical
Publication of CA2898565C publication Critical patent/CA2898565C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01B—SOIL WORKING IN AGRICULTURE OR FORESTRY; PARTS, DETAILS, OR ACCESSORIES OF AGRICULTURAL MACHINES OR IMPLEMENTS, IN GENERAL
    • A01B1/00—Hand tools
    • A01B1/02—Spades; Shovels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Environmental Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Soil Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2898565A 2013-02-20 2014-02-18 Treatment of graft versus host disease in transplant patients Active CA2898565C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361766830P 2013-02-20 2013-02-20
US61/766,830 2013-02-20
PCT/IB2014/059067 WO2014128611A1 (en) 2013-02-20 2014-02-18 Treatment of graft versus host disease in transplant patients

Publications (2)

Publication Number Publication Date
CA2898565A1 CA2898565A1 (en) 2014-08-28
CA2898565C true CA2898565C (en) 2023-01-24

Family

ID=50236228

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2898565A Active CA2898565C (en) 2013-02-20 2014-02-18 Treatment of graft versus host disease in transplant patients

Country Status (23)

Country Link
US (2) US20160000811A1 (cg-RX-API-DMAC7.html)
EP (1) EP2958624B1 (cg-RX-API-DMAC7.html)
JP (2) JP6441822B2 (cg-RX-API-DMAC7.html)
KR (1) KR102165514B1 (cg-RX-API-DMAC7.html)
CN (1) CN105007981B (cg-RX-API-DMAC7.html)
AU (1) AU2014220377B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015019197A2 (cg-RX-API-DMAC7.html)
CA (1) CA2898565C (cg-RX-API-DMAC7.html)
CY (1) CY1124191T1 (cg-RX-API-DMAC7.html)
DK (1) DK2958624T3 (cg-RX-API-DMAC7.html)
EA (1) EA030783B1 (cg-RX-API-DMAC7.html)
ES (1) ES2873181T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210891T1 (cg-RX-API-DMAC7.html)
HU (1) HUE054330T2 (cg-RX-API-DMAC7.html)
LT (1) LT2958624T (cg-RX-API-DMAC7.html)
MX (1) MX369631B (cg-RX-API-DMAC7.html)
PL (1) PL2958624T3 (cg-RX-API-DMAC7.html)
PT (1) PT2958624T (cg-RX-API-DMAC7.html)
RS (1) RS61933B1 (cg-RX-API-DMAC7.html)
SI (1) SI2958624T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100334T1 (cg-RX-API-DMAC7.html)
TW (1) TWI648050B (cg-RX-API-DMAC7.html)
WO (1) WO2014128611A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190022033A1 (en) * 2016-03-08 2019-01-24 Kyorin Pharmaceutical Co., Ltd. Treatment of hematopoietic stem cell transplant patients
KR20210040954A (ko) 2018-07-27 2021-04-14 프리오테라 리미티드 조혈 줄기세포 이식을 받은 환자에 있어서의 혈액 악성 종양의 재발 억제제
CN117177748A (zh) * 2020-11-04 2023-12-05 浩康生物系统公司 用于异基因造血干细胞移植的方法
AU2021424131A1 (en) 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
MX2023008907A (es) 2021-01-28 2023-08-09 Priothera Sas Metodos de tratamiento con moduladores del receptor de esfingosina-1-fosfato (s1p).
AU2023220748A1 (en) 2022-02-16 2024-07-25 Priothera Sas Methods of treatment with car cells in combination with s1p receptor modulators
EP4282407A1 (en) 2022-05-27 2023-11-29 Priothera SAS Treatment of cancer with s1p receptor agonists
WO2025109119A1 (en) 2023-11-22 2025-05-30 Priothera Sas Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2271464A1 (en) * 1996-11-15 1998-05-22 Baxter International Inc. Conditioning for allogeneic stem cell transplantation
US6383481B1 (en) 1998-03-30 2002-05-07 Japan Immunoresearch Laboratories Co., Ltd. Method for transplantation of hemopoietic stem cells
JPH11343242A (ja) * 1998-03-30 1999-12-14 Otsuka Pharmaceut Co Ltd 造血幹細胞移植用剤
DE60223699T2 (de) * 2001-09-27 2008-10-30 Kyorin Pharmaceutical Co., Ltd. Diarylsulfidderivat, dessen additionssalz und immunsuppressivum
WO2004026817A1 (ja) * 2002-09-19 2004-04-01 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
CN101014329B (zh) * 2004-07-16 2010-09-08 杏林制药株式会社 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物
WO2006073126A1 (ja) * 2005-01-06 2006-07-13 Kissei Pharmaceutical Co., Ltd. 慢性移植片対宿主症におけるドライアイの予防および治療剤
ES2686424T5 (es) 2010-05-04 2023-03-27 Yeda Res & Dev Inmunoterapia con células alogénicas redireccionadas
CA2794607A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Dosage regimen of diaryl sulfide derivatives

Also Published As

Publication number Publication date
KR102165514B1 (ko) 2020-10-15
EA030783B1 (ru) 2018-09-28
US11224604B2 (en) 2022-01-18
WO2014128611A1 (en) 2014-08-28
PL2958624T3 (pl) 2021-10-04
US20160000811A1 (en) 2016-01-07
CN105007981B (zh) 2020-07-21
JP2019059748A (ja) 2019-04-18
JP6441822B2 (ja) 2018-12-19
BR112015019197A2 (pt) 2017-07-18
MX369631B (es) 2019-11-14
HRP20210891T1 (hr) 2021-07-23
CA2898565A1 (en) 2014-08-28
JP6633170B2 (ja) 2020-01-22
EP2958624B1 (en) 2021-05-12
TWI648050B (zh) 2019-01-21
ES2873181T3 (es) 2021-11-03
MX2015010833A (es) 2016-07-08
EP2958624A1 (en) 2015-12-30
LT2958624T (lt) 2021-08-10
JP2016509050A (ja) 2016-03-24
AU2014220377A1 (en) 2015-08-06
PT2958624T (pt) 2021-06-11
SI2958624T1 (sl) 2021-07-30
HUE054330T2 (hu) 2021-09-28
CN105007981A (zh) 2015-10-28
DK2958624T3 (da) 2021-06-07
AU2014220377B2 (en) 2017-05-04
RS61933B1 (sr) 2021-07-30
TW201511751A (zh) 2015-04-01
CY1124191T1 (el) 2022-05-27
SMT202100334T1 (it) 2021-07-12
EA201591522A1 (ru) 2016-03-31
KR20150118149A (ko) 2015-10-21
US20180153911A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
CA2898565C (en) Treatment of graft versus host disease in transplant patients
JP7788114B2 (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
JP6453441B2 (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤
TW201817425A (zh) 用於治療非酒精性脂肪肝疾病之醫藥組成物及方法
JP2016509050A5 (cg-RX-API-DMAC7.html)
US11622965B2 (en) Methods for treating lymphoid malignancies
Raderer et al. Role of chemotherapy in gastric MALT lymphoma, diffuse large B-cell lymphoma and other lymphomas
JP2024506825A (ja) Ｓ１ｐ受容体調節剤による処置の方法
WO2012151541A1 (en) Csf-1r inhibitors for treatment of brain tumors
JP2020532555A (ja) ダントロレンを使用して神経薬暴露を治療する方法
EP3426279B1 (en) Treatment of hematopoietic stem cell transplant patients
CN111195250A (zh) 西达本胺联合dice的应用及联合药物
EP3265075B1 (en) Roneparstat combined therapy of multiple myeloma
JP2022510258A (ja) デビミスタットを使用して急性骨髄性白血病を治療するための治療方法および組成物
HK40025659B (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
HK40025659A (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
HK40013523A (en) Prophylactic and therapeutic drug for nonalcoholic fatty liver disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181130

EEER Examination request

Effective date: 20181130

EEER Examination request

Effective date: 20181130

EEER Examination request

Effective date: 20181130